Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06533059
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-25
Brief Title:
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
AKTive-001 A Phase 11b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors
Detailed Description:
This is an open-label multicenter Phase 11b study of ALTA2618 a mutant-selective and orally bioavailable AKT1 E17K inhibitor in adults with AKT1 E17K-mutant solid tumors This study will evaluate the safety tolerability pharmacokinetics PK and preliminary clinical activity of ALTA2618 and aims to find the best dose The study consists of two parts Part 1 - Dose Escalation and Part 1b - Dose Expansion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None